PATENT CLAIM ANALYSIS

Application Number: 15864494
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "227100"]

Abstract:
Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Claim (Index 11):
An antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region CDR1, CDR2, and CDR3 domains are selected from the group consisting of:\n a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-10 of SEQ ID NO: 59, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 60, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-11 of SEQ ID NO: 61; b) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 5-9 of SEQ ID NO: 65, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 66, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 67; c) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-10 of SEQ ID NO: 71, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 72, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-7 of SEQ ID NO: 73; d) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 77, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 78, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-13 of SEQ ID NO: 79; e) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-10 of SEQ ID NO: 83, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 84, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-9 of SEQ ID NO: 85; f) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 89, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 90, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 91; a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-10 of SEQ ID NO: 95, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 96, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-12 of SEQ ID NO: 97; g) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 101, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 102, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 103; h) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 104, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 105, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 106; i) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 107, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 108, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 109; j) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 110, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 111, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 112; k) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 113, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 114, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 115; l) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 116, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 117, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 118; m) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 119, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 120, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 121; n) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 122, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 123, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-9 of SEQ ID NO: 124; o) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 125, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 126, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 127; and p) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in residues 6-12 of SEQ ID NO: 128, a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 129, and a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in residues 3-10 of SEQ ID NO: 130.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 1.47222
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15766593', '12322861', '13466439', '14449478', '15302018']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7588936736669868
- 35 USC 102 Novelty (BERT): 0.5262035028126175
- Combined Prediction Score: 0.7356246565815499
- Mean Citation Score: 341.3386900000001
- Max Citation Score: 354.49304
- Similarity Product: 282.5135390165854

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test